Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dexcom (DXCM) Shares Outstanding (Weighted Average) (2016 - 2026)

Dexcom has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $385.1 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) fell 1.53% to $385.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $385.1 million through Mar 2026, down 1.53% year-over-year, with the annual reading at $390.2 million for FY2025, 0.86% down from the prior year.
  • Shares Outstanding (Weighted Average) was $385.1 million for Q1 2026 at Dexcom, down from $390.2 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $394.8 million in Q2 2024 and troughed at $385.1 million in Q1 2026.
  • The 5-year median for Shares Outstanding (Weighted Average) is $390.2 million (2024), against an average of $389.9 million.
  • Year-over-year, Shares Outstanding (Weighted Average) surged 303.84% in 2022 and then decreased 1.53% in 2026.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $389.4 million in 2022, then decreased by 0.87% to $386.0 million in 2023, then rose by 1.97% to $393.6 million in 2024, then dropped by 0.86% to $390.2 million in 2025, then dropped by 1.31% to $385.1 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Shares Outstanding (Weighted Average) are $385.1 million (Q1 2026), $390.2 million (Q4 2025), and $391.1 million (Q3 2025).